Related Experiment Video
Updated: Mar 12, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
4.5K
Corticosteroids and Anti-Complement Therapy in Retinal Diseases.
Raja Narayanan1, Baruch D Kuppermann2
1Smt Kanuri Santhamma Vitreoretina Center, L.V. Prasad Eye Institute, Hyderabad, India.
Handbook of Experimental Pharmacology
|November 6, 2016
Summary
Corticosteroids effectively treat macular edema by targeting multiple pathways. Complement inhibitors show promise for dry age-related macular degeneration (AMD), with clinical trials ongoing.
Area of Science:
- Ophthalmology and Pharmacology
- Retinal and Choroidal Vascular Diseases
- Age-Related Macular Degeneration (AMD) Pathogenesis
Background:
- Macular edema involves complex pathophysiological processes.
- Corticosteroids are versatile agents impacting multiple pathways in macular edema.
- Complement factors are implicated in the pathogenesis of dry age-related macular degeneration (AMD).
Purpose of the Study:
- To review the multifaceted role of corticosteroids in treating macular edema.
- To explore the potential of complement inhibitors as a novel therapeutic strategy for dry AMD.
Main Methods:
- Review of corticosteroid mechanisms, including inhibition of prostaglandin, leukotriene synthesis, and key inflammatory pathways (ICAM-1, IL-6, VEGF-A, SDF-1).
- Discussion of sustained-release steroid implants for retinal diseases.
- Examination of complement factor inhibitors (POT-4, lampalizumab, eculizumab) in dry AMD clinical trials.
Main Results:
- Corticosteroids (triamcinolone, dexamethasone, fluocinolone) are established treatments for retinal and choroidal vascular diseases.
- Sustained-release steroid implants offer an improved delivery method, reducing injection frequency.
- Complement inhibitors have demonstrated promising preliminary results in clinical trials for dry AMD.
Conclusions:
- Corticosteroids remain a cornerstone therapy for various macular edema etiologies due to their broad mechanism of action.
- Targeting complement pathways represents a potential breakthrough for treating dry AMD.
- Further phase 3 trial results are anticipated to confirm the efficacy of complement inhibitors.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K